期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 23, 页码 -出版社
MDPI
DOI: 10.3390/ijms222312952
关键词
cancer; organoselenium compounds; selenomethionine; selenocysteine; methylselenocysteine; histone deacetylation
资金
- National Research Foundation [120820]
This review discusses the impact of organoselenium compounds on cancer therapy, and their role in regulating the acetylation status of histones and non-histone proteins.
Genetic and epigenetic changes alter gene expression, contributing to cancer. Epigenetic changes in cancer arise from alterations in DNA and histone modifications that lead to tumour suppressor gene silencing and the activation of oncogenes. The acetylation status of histones and non-histone proteins are determined by the histone deacetylases and histone acetyltransferases that control gene transcription. Organoselenium compounds have become promising contenders in cancer therapeutics. Apart from their anti-oxidative effects, several natural and synthetic organoselenium compounds and metabolites act as histone deacetylase inhibitors, which influence the acetylation status of histones and non-histone proteins, altering gene transcription. This review aims to summarise the effect of natural and synthetic organoselenium compounds on histone and non-histone protein acetylation/deacetylation in cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据